Axsome Therapeutics, Inc. (AXSM)

26.46 +2.33 (+9.66%) At close: 04:00PM EDT

Axsome Therapeutics, Inc.

22 Cortlandt Street
16th Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 116

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & Pres	1.06M	N/A	1968
Mr. Nick Pizzie CPA, M.B.A.	Chief Financial Officer	553.97k	N/A	1975
Mr. Mark L. Jacobson	COO & Sec.	554.72k	N/A	1983
Mr. Hunter Murdock Esq.	Exec. VP of Legal & Compliance	N/A	N/A	N/A
Dr. Amanda Jones Pharm.D.	Sr. VP of Clinical Devel.	N/A	N/A	1983
Ms. Lori Englebert M.B.A.	Exec. VP of Commercial & Bus. Devel.	N/A	N/A	1978
Mr. Kevin Laliberte Pharm.D.	Exec. VP of Product Strategy	N/A	N/A	1978
Joseph Debrah-Afful CPA, M.B.A.	Director of Fin.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corporate Governance

Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.